|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng TY, Cramb SM, Baade PD, Youlden DR,
Nwogu C and Reid ME: The international epidemiology of lung cancer:
Latest trends, disparities, and tumor characteristics. J Thorac
Oncol. 11:1653–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Derman BA, Mileham KF, Bonomi PD, Batus M
and Fidler MJ: Treatment of advanced squamous cell carcinoma of the
lung: A review. Transl Lung Cancer Res. 4:524–532. 2015.PubMed/NCBI
|
|
6
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gandara DR. Hammerman PS, Sos ML, Lara PN
Jr and Hirsch FR: Squamous cell lung cancer: From tumor genomics to
cancer therapeutics. Clin Cancer Res. 21:2236–2243. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kennedy GT, Azari FS, Bernstein E, Nadeem
B, Chang AE, Segil A, Sullivan N, Marfatia I, Din A, Desphande C,
et al: A prostate-specific membrane antigen-targeted near-infrared
conjugate for identifying pulmonary squamous cell carcinoma during
resection. Mol Cancer Ther. 21:546–554. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xia L, Liu Y and Wang Y: PD-1/PD-L1
blockade therapy in advanced non-small-cell lung cancer: Current
status and future directions. Oncologist. 24 (Suppl 1):S31–S41.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang ZF, Liu J, Yang YA and Zhu HL: A
review: The anti-inflammatory, anticancer and antibacterial
properties of four kinds of licorice flavonoids isolated from
licorice. Curr Med Chem. 27:1997–2011. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bortolotto LF, Barbosa FR, Silva G,
Bitencourt TA, Beleboni RO, Baek SJ, Marins M and Fachin AL:
Cytotoxicity of trans-chalcone and licochalcone A against breast
cancer cells is due to apoptosis induction and cell cycle arrest.
Biomed Pharmacother. 85:425–433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lv H, Ren H, Wang L, Chen W and Ci X: Lico
A enhances Nrf2-mediated defense mechanisms against t-BHP-induced
oxidative stress and cell death via Akt and ERK activation in RAW
264.7 cells. Oxid Med Cell Longev. 2015:7098452015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Freitas KS, Squarisi IS, Acesio NO,
Nicolella HD, Ozelin SD, Reis Santos de Melo M, Guissone APP,
Fernandes G, Silva LM, da Silva Filho AA and Tavares DC:
Licochalcone A, a licorice flavonoid: Antioxidant, cytotoxic,
genotoxic, and chemopreventive potential. J Toxicol Environ Health
A. 83:673–686. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D
and Zheng Q: Licochalcone A-induced human gastric cancer BGC-823
cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT
signaling pathways. Sci Rep. 5:103362015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li MT, Xie L, Jiang HM, Huang Q, Tong RS,
Li X, Xie X and Liu HM: Role of licochalcone A in potential
pharmacological therapy: A review. Front Pharmacol. 13:8787762022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin M, Xu Y, Gao Y, Pan C, Zhu X and Wang
ZW: Regulation of F-box proteins by noncoding RNAs in human
cancers. Cancer Lett. 466:61–70. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song Y, Lin M, Liu Y, Wang ZW and Zhu X:
Emerging role of F-box proteins in the regulation of
epithelial-mesenchymal transition and stem cells in human cancers.
Stem Cell Res Ther. 10:1242019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reimann JD, Gardner BE, Margottin-Goguet F
and Jackson PK: Emi1 regulates the anaphase-promoting complex by a
different mechanism than Mad2 proteins. Genes Dev. 15:3278–3285.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miller JJ, Summers MK, Hansen DV, Nachury
MV, Lehman NL, Loktev A and Jackson PK: Emi1 stably binds and
inhibits the anaphase-promoting complex/cyclosome as a
pseudosubstrate inhibitor. Genes Dev. 20:2410–2420. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Di Fiore B and Pines J: Defining the role
of Emi1 in the DNA replication-segregation cycle. Chromosoma.
117:333–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vaidyanathan S, Cato K, Tang L, Pavey S,
Haass NK, Gabrielli BG and Duijf PHG: In vivo overexpression of
Emi1 promotes chromosome instability and tumorigenesis. Oncogene.
35:5446–5455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Wang H, Ma J, Xu J, Sheng C, Yang
S, Sun L and Ni Q: The expression and prognosis of Emi1 and Skp2 in
breast carcinoma: Associated with PI3K/Akt pathway and cell
proliferation. Med Oncol. 30:7352013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guan C, Zhang J, Zhang J, Shi H and Ni R:
Enhanced expression of early mitotic inhibitor-1 predicts a poor
prognosis in esophageal squamous cell carcinoma patients. Oncol
Lett. 12:114–120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang K, Qu X, Liu S, Yang X, Bie F, Wang
Y, Huang C and Du J: Identification of aberrantly expressed F-box
proteins in squamous-cell lung carcinoma. J Cancer Res Clin Oncol.
144:1509–1521. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pinzi L and Rastelli G: Molecular docking:
Shifting paradigms in drug discovery. Int J Mol Sci. 20:43312019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li F, Wang L, Cai Y, Luo Y and Shi X:
Safety assessment of desaminotyrosine: Acute, subchronic oral
toxicity, and its effects on intestinal microbiota in rats. Toxicol
Appl Pharmacol. 417:1154642021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Friedlaender A, Banna G, Malapelle U,
Pisapia P and Addeo A: Next generation sequencing and genetic
alterations in squamous cell lung carcinoma: Where are we today?
Front Oncol. 9:1662019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hosseinzadeh H and Nassiri-Asl M:
Pharmacological effects of Glycyrrhiza spp. and its bioactive
constituents: Update and review. Phytother Res. 29:1868–1886. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li K, Ji S, Song W, Kuang Y, Lin Y, Tang
S, Cui Z, Qiao X, Yu S and Ye M: Glycybridins A-K, bioactive
phenolic compounds from Glycyrrhiza glabra. J Nat Prod. 80:334–346.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song W, Si L, Ji S, Wang H, Fang XM, Yu
LY, Li RY, Liang LN, Zhou D and Ye M: Uralsaponins M-Y, antiviral
triterpenoid saponins from the roots of Glycyrrhiza uralensis. J
Nat Prod. 77:1632–1643. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao F, Li M, Yu X, Liu W, Zhou L and Li W:
Licochalcone A inhibits EGFR signalling and translationally
suppresses survivin expression in human cancer cells. J Cell Mol
Med. 25:813–826. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu KD, Miao Y, Li P, Li PP, Liu J, Li J
and Cao F: Licochalcone A inhibits cell growth through the
downregulation of the Hippo pathway via PES1 in cholangiocarcinoma
cells. Environ Toxicol. 37:564–573. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu C, Zuo Y, Liu J, Xu H, Liao W, Dang Y,
Luo C, Tang L and Zhang H: Licochalcone A suppresses the
proliferation of sarcoma HT-1080 cells, as a selective R132C mutant
IDH1 inhibitor. Bioorg Med Chem Lett. 30:1268252020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mori M, Bogdan A, Balassa T, Csabai T and
Szekeres-Bartho J: The decidua-the maternal bed embracing the
embryo-maintains the pregnancy. Semin Immunopathol. 38:635–649.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chang Z, Kuang HX, Zhou X, Zhu H, Zhang Y,
Fu Y, Fu Q, Jiang B, Wang W, Jiang S, et al: Temporal changes in
cyclinD-CDK4/CDK6 and cyclinE-CDK2 pathways: Implications for the
mechanism of deficient decidualization in an immune-based mouse
model of unexplained recurrent spontaneous abortion. Mol Med.
28:1002022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu P, Yu T, Wu J and Chen J: Licochalcone
a induces ROS-mediated apoptosis through TrxR1 inactivation in
colorectal cancer cells. Biomed Res Int.
2020:58750742020.PubMed/NCBI
|
|
41
|
Morana O, Wood W and Gregory CD: The
apoptosis paradox in cancer. Int J Mol Sci. 23:13282022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Khodavirdipour A, Piri M, Jabbari S,
Keshavarzi S, Safaralizadeh R and Alikhani MY: Apoptosis detection
methods in diagnosis of cancer and their potential role in
treatment: Advantages and disadvantages: A review. J Gastrointest
Cancer. 52:422–430. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ji Q, Zhu F, Liu X, Li Q and Su SB: Recent
advance in applications of proteomics technologies on traditional
Chinese medicine research. Evid Based Complement Alternat Med.
2015:9831392015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Monti C, Zilocchi M, Colugnat I and
Alberio T: Proteomics turns functional. J Proteomics. 198:36–44.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yong HY, Koh MS and Moon A: The p38 MAPK
inhibitors for the treatment of inflammatory diseases and cancer.
Expert Opin Investig Drugs. 18:1893–1905. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Greenberg AK, Basu S, Hu J, Yie TA,
Tchou-Wong KM, Rom WN and Lee TC: Selective p38 activation in human
non-small cell lung cancer. Am J Respir Cell Mol Biol. 26:558–564.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sugiura R, Satoh R and Takasaki T: ERK: A
double-edged sword in cancer. ERK-dependent apoptosis as a
potential therapeutic strategy for cancer. Cells. 10:25092021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Marzio A, Puccini J, Kwon Y, Maverakis NK,
Arbini A, Sung P, Bar-Sagi D and Pagano M: The F-box
domain-dependent activity of EMI1 regulates PARPi sensitivity in
triple-negative breast cancers. Mol Cell. 73:224–237.e6. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu
C, Shen A, Wang Y, Li C, Yuan Q, et al: Early mitotic inhibitor-1,
an anaphase-promoting complex/cyclosome inhibitor, can control
tumor cell proliferation in hepatocellular carcinoma: Correlation
with Skp2 stability and degradation of p27(Kip1). Hum Pathol.
44:365–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
McHugh A, Fernandes K, Chinner N, Ibrahim
AFM, Garg AK, Boag G, Hepburn LA, Proby CM, Leigh IM and Saville
MK: The identification of potential therapeutic targets for
cutaneous squamous cell carcinoma. J Invest Dermatol.
140:1154–1165.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu P, Wang X, Pan L, Han B and He Z:
Prognostic significance and immunological role of FBXO5 in human
cancers: A systematic pan-cancer analysis. Front Immunol.
13:9017842022. View Article : Google Scholar : PubMed/NCBI
|
